Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20416874 | 0.86 | IRAK4 (0.34) | IRAK4KCNH2BACE1 | |
| SCHEMBL20416619 | 0.85 | IRAK4 (0.34) | IRAK4KCNH2BACE1 | |
| SCHEMBL23355664 | 0.84 | IRAK4 (0.33) | IRAK4MBOAT4KCNH2BACE1 | |
| SCHEMBL20436450 | 0.84 | KCNH2 (0.34) | IRAK4MBOAT4KCNH2BACE1 | |
| SCHEMBL536722 | 0.81 | HCRTR1 (0.41) | IRAK4 | |
| SCHEMBL929267 | 0.81 | KCNH2 (0.38) | IRAK4KCNH2BACE1 | |
| SCHEMBL536792 | 0.80 | HSD17B10 (0.33) | IRAK4KCNH2BACE1 | |
| SCHEMBL5466523 | 0.79 | KCNH2 (0.39) | IRAK4KCNH2BACE1 | |
| SCHEMBL4712759 | 0.78 | HRH1 (0.37) | TAAR1IRAK4KCNH2BACE1 | |
| SCHEMBL20416670 | 0.78 | MBOAT4 (0.47) | IRAK4MBOAT4KCNH2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399962-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | TAAR1 1068/4885IRAK4 759/4885MBOAT4 4806/4885 |
| US-10399962-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | TAAR1 1068/4885IRAK4 759/4885MBOAT4 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.